Immunotherapy, notably immune checkpoint inhibitors targeting PD‐1 and CTLA‐4, has revolutionized the treatment paradigm of SKCM by augmenting anti‐tumor immunity and improving patient outcomes. The gene discussed is CTLA4; the disease is neoplasm.